HUP0303721A2 - Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303721A2
HUP0303721A2 HU0303721A HUP0303721A HUP0303721A2 HU P0303721 A2 HUP0303721 A2 HU P0303721A2 HU 0303721 A HU0303721 A HU 0303721A HU P0303721 A HUP0303721 A HU P0303721A HU P0303721 A2 HUP0303721 A2 HU P0303721A2
Authority
HU
Hungary
Prior art keywords
drug
releasing factor
imidazo
preparation
pharmaceutical compositions
Prior art date
Application number
HU0303721A
Other languages
English (en)
Inventor
Bireshwar Dasgupta
Gene M. Dubowchik
Xiaojun Han
Jodi A. Michne
Vivekananda M. Vrudhula
Dmitry Zuev
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0303721A2 publication Critical patent/HUP0303721A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

A találmány tárgyát kortikotripin releasing faktor-receptor (CRF-receptor) antagonista tulajdonságú, a depresszió, szorongás, affektívbetegségek, táplálkozási betegségek, poszttraumás stresszbetegség;fejfájás, gyógyszer- és kábítószer-függőség, gyulladásos betegségek,kábítószer- és alkoholelvonási tünetek és más, a CRF-receptorokantagonizálásával befolyásolható kóros állapotok kezelésérehasználható általános képletű új vegyületek - ahol előnyösen R1 alkil-vagy halogén-alkil-csoport; R2 N,N-diszubsztituált karbamoil- vagyamino-metil-csoport, és X és Y szénatom, amely az A szimbólummalegyütt egy nitrogénatomján 2 vagy 3 azonos vagy különbözőszubsztituenst hordozó fenilcsoporttal, továbbá adott esetben főkénthalogénatommal szubsztituált imidazo[1,2-a]imidazol-, imidazo[1,2-a]-pirimidin-, valamint 1,3a,8-triaza- vagy 1,3a,7,8-tetraaza-ciklopenta[a]indén-vázat képez - és gyógyszerészetileg elfogadhatósóik vagy szolvátjaik és ezeket tartalmazó gyógyszerkészítményekképezik. Ó
HU0303721A 2001-01-26 2002-01-11 Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények HUP0303721A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26457001P 2001-01-26 2001-01-26
PCT/US2002/000841 WO2002058704A1 (en) 2001-01-26 2002-01-11 Imidazolyl derivatives as corticotropin releasing factor inhibitors

Publications (1)

Publication Number Publication Date
HUP0303721A2 true HUP0303721A2 (hu) 2004-03-01

Family

ID=23006646

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303721A HUP0303721A2 (hu) 2001-01-26 2002-01-11 Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Country Status (22)

Country Link
US (5) US6888004B2 (hu)
EP (1) EP1359916A4 (hu)
JP (1) JP2004531475A (hu)
KR (1) KR20040034594A (hu)
CN (1) CN1499972A (hu)
BG (1) BG107999A (hu)
BR (1) BR0206698A (hu)
CA (1) CA2434558A1 (hu)
CZ (1) CZ20032044A3 (hu)
EE (1) EE200300342A (hu)
HR (1) HRP20030675A2 (hu)
HU (1) HUP0303721A2 (hu)
IL (1) IL156813A0 (hu)
IS (1) IS6889A (hu)
MX (1) MXPA03006484A (hu)
NO (1) NO20033350L (hu)
PE (1) PE20020844A1 (hu)
PL (1) PL368555A1 (hu)
RU (1) RU2003126188A (hu)
SK (1) SK9222003A3 (hu)
WO (1) WO2002058704A1 (hu)
ZA (1) ZA200305531B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200300342A (et) * 2001-01-26 2003-12-15 Bristol-Myers Squibb Company Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
HUP0401292A3 (en) 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
DE60326869D1 (de) 2002-10-22 2009-05-07 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2008157302A2 (en) 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
NZ585640A (en) * 2007-11-29 2011-03-31 Boehringer Ingelhelheim Internat Gmbh Derivatives of 6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3- carboxylic acid amides
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
US7994203B2 (en) * 2008-08-06 2011-08-09 Novartis Ag Organic compounds
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AR080055A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
CN106188065B (zh) * 2011-03-25 2021-12-28 Udc 爱尔兰有限责任公司 用于电子应用的4H-咪唑并[1,2-a]咪唑
US9806270B2 (en) 2011-03-25 2017-10-31 Udc Ireland Limited 4H-imidazo[1,2-a]imidazoles for electronic applications
CN108440531B (zh) 2011-11-10 2021-11-02 Udc 爱尔兰有限责任公司 用于电子应用的4H-咪唑并[1,2-a]咪唑
TWI644888B (zh) 2012-02-07 2018-12-21 拜耳智慧財產有限公司 用於製備經取代之鄰胺苯甲酸衍生物之方法
US10538475B2 (en) 2012-05-25 2020-01-21 Nutech Ventures Amphiphilic cyclobutenes and cylobutanes
WO2014009317A1 (en) 2012-07-10 2014-01-16 Basf Se Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105384691B (zh) * 2015-10-26 2018-06-29 深圳大学 一种谷氨酰胺酰基环化酶抑制剂的制备方法及应用
CA3069736A1 (en) 2017-07-24 2019-01-31 University Of South Florida Novel bis-cyclic guanidines as antibacterial agents
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
DE2827617A1 (de) * 1978-06-23 1980-01-10 Boehringer Sohn Ingelheim Neue imidazo eckige klammer auf 1,2- alpha eckige klammer zu imidazole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
IL69417A (en) * 1982-08-27 1987-12-20 Roussel Uclaf 2-acyl imidazo(1,2-a)pyrimidines,their preparation and pharmaceutical compositions containing them
US4551530A (en) * 1984-11-19 1985-11-05 American Cyanamid Company Pyridyl imidazo[1,2-a]pyrimidines
DK155524C (da) * 1987-03-18 1989-09-11 Ferrosan As Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
JPH05107705A (ja) * 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ATE172975T1 (de) * 1992-05-19 1998-11-15 Adir Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2722501B1 (fr) * 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
CN1090189C (zh) * 1996-02-07 2002-09-04 詹森药业有限公司 吡唑并嘧啶类化合物
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
EP0970958A4 (en) * 1996-10-03 2000-01-12 Nissan Chemical Ind Ltd PYRIMIDINONE DERIVATIVES WITH FUSED HETEROCYCLE AND HERBICIDES
EP0970082A2 (en) 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
WO1999001454A1 (en) 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
WO1999010350A1 (en) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
BR9803368A (pt) 1997-09-05 2001-04-24 Sumitomo Chemical Co Derivados de perimidona e herbecidas contendo os mesmos
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
DE69831690T2 (de) * 1997-12-26 2006-06-29 Takeda Pharmaceutical Co. Ltd. Stickstoffhaltige heterocyclische verbindungen, ihre herstellung und verwendung
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA03000914A (es) * 2000-08-09 2003-10-06 Boehringer Ingelheim Pharma Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona.
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
WO2002024200A1 (en) * 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
EE200300342A (et) * 2001-01-26 2003-12-15 Bristol-Myers Squibb Company Imidasolüüli derivaadid kui kortikotropiini vabastava faktori inhibiitorid, nende saamismeetodid ning kasutamine

Also Published As

Publication number Publication date
BG107999A (en) 2004-08-31
MXPA03006484A (es) 2003-09-22
KR20040034594A (ko) 2004-04-28
BR0206698A (pt) 2004-04-20
IL156813A0 (en) 2004-02-08
CA2434558A1 (en) 2002-08-01
US20040225130A1 (en) 2004-11-11
US6888004B2 (en) 2005-05-03
EP1359916A4 (en) 2004-04-07
JP2004531475A (ja) 2004-10-14
US7238699B2 (en) 2007-07-03
US20040235924A1 (en) 2004-11-25
US20040225001A1 (en) 2004-11-11
SK9222003A3 (en) 2004-05-04
NO20033350L (no) 2003-09-22
US7244746B2 (en) 2007-07-17
ZA200305531B (en) 2004-07-27
WO2002058704A1 (en) 2002-08-01
RU2003126188A (ru) 2005-03-27
PL368555A1 (en) 2005-04-04
US20040254382A1 (en) 2004-12-16
EE200300342A (et) 2003-12-15
HRP20030675A2 (en) 2004-08-31
CN1499972A (zh) 2004-05-26
US7125990B2 (en) 2006-10-24
US7211669B2 (en) 2007-05-01
CZ20032044A3 (cs) 2003-12-17
IS6889A (is) 2003-07-24
NO20033350D0 (no) 2003-07-25
EP1359916A1 (en) 2003-11-12
US20020183375A1 (en) 2002-12-05
PE20020844A1 (es) 2002-09-27

Similar Documents

Publication Publication Date Title
HUP0303721A2 (hu) Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6133274A (en) Hydroxyl-containing bicyclic compounds
US5889011A (en) Substituted amino alkyl compounds
KR20170103838A (ko) 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제
CA2758474A1 (en) Novel p2x7r antagonists and their use
HUP0102851A2 (hu) Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0401876A2 (hu) Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
DK0672031T3 (da) Catecholdiethere som selektive PDE IV-inhibitorer
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
JPH09500908A (ja) ジヒドロピラゾロピロール類
HUP0301745A2 (hu) Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2006503048A5 (hu)
JPH07502739A (ja) ５−ｈｔレセプター拮抗物質としてのピペラジン誘導体
HUP0301236A2 (hu) Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
EP0623133B1 (en) Substituted amino alkyl compounds
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
CA2151617A1 (en) Hydroxyl-containing compounds
HUP0303630A2 (hu) Imidazo-pirimidin-származékok, mint GABA receptorok ligandumai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0303034A2 (hu) Új 7-azaindol-származékok, foszfodiészteráz-4 inhibitorjakénti alkalmazásuk és eljárás az előállításukra
HUP0301458A2 (hu) Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
HUP0003413A2 (hu) Új kondenzált piridinszármazékok, eljárás előállításukra és az azokat tartalmazó gyógyászati készítmények
HUP0303480A2 (hu) 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.